Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Department of Immunology, Pasteur Institute of Iran, Tehran, IR, Iran
Research Article
Treatment of Experimental Cutaneous Leishmaniasis by the Therapeutic Vaccine SLA-R848-Pam3CSK4
Author(s): Asal Katebi, Farhad Riazi-rad and Soheila Ajdary*
Background: Leishmaniasis is a vector-borne disease affecting 12 million people in the world. Because of the high prevalence of this disease and also problems related to the control and therapy of leishmaniasis, the development of effective and applicable therapeutic approaches in the treatment of leishmaniasis seems to be essential. In recent years, therapeutic vaccines have been considered promising approaches against leishmaniasis. So, we examined the therapeutic efficacy of Soluble Leishmania antigen (SLA) in combination with TLR agonists (R848 and Pam3CSK4) as adjuvants using the BALB/c mice model.
Methods: To develop a new therapeutic vaccine for leishmaniasis, SLA and/or Pam3CSK4 and/or R848 were injected one week after infection three times. One week after infection, footpad swelling was monitored weekly. Parasite .. View More»